While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M.

Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...

The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...

ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...

NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.

Longitudinal ALS patient data from APST Research will enable a more robust analysis of the effect of CNM-Au8 on NfL biomarkers; APST Research data includes thousands of people liv ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Four ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

All four trials, part of the Massachusetts General Hospital’s HEALEY ALS platform trial (NCT05136885), failed to show an impact on ALS disease progression. The platform trial is examining ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ...